ASA404. Vascular-disrupting agent, oncolytic

Drugs of the Future

Volumn 33, Issue 7, 2008, Pages 561-569

  Ching, L M ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLAVONE DERIVATIVE; FLAVONOID; MELPHALAN; MITOFLAXONE; PACLITAXEL; TAXANE DERIVATIVE; THALIDOMIDE; VINCRISTINE;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANXIETY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER INHIBITION; CLINICAL TRIAL; COLON TUMOR; CONFUSION; CYTOKINE PRODUCTION; DECARBOXYLATION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MORTALITY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; PLASMA HALF LIFE; PLASMA PROTEIN BINDING; PROSTATE CANCER; QT PROLONGATION; SIDE EFFECT; SLURRED SPEECH; SURVIVAL TIME; TREMOR; TUMOR BLOOD FLOW; TUMOR NECROSIS; TUMOR REGRESSION; TUMOR VASCULARIZATION; URINE INCONTINENCE; VISUAL DISORDER;

EID: 56749151224     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.07.1216922     Document Type: Article

References (71)

1. Rewcastle, G.W., Atwell, G.J., Li, Z.A., Baguley, B.C., Denny, W.A. Potential antitumour agents. 61. Structure-activity relationships for in vivo colon-38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 1991, 34(1): 217-22.
2. Atwell, G.J., Yang, S., Denny, W.A. An improved synthesis of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Eur J Med Chem 2002, 37(10): 825-8.
3. Denny, W.A., Baguley, B.C., Atwell, G.J., Rewcastle, G.W. (Cancer Research UK; Pfizer, Inc.). Compounds having antitumour and antibacterial properties. EP 0278176, US 5281620.
4. Rewcastle, G.W., Kestell, P., Baguley, B.C., Denny, W.A. Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution. J Natl Cancer Inst 1990, 82(6): 528-9.
5. Palmer, B.D., Henare, K., Woon, S.-T. et al. Synthesis and biological activity of azido analogues of 5,6-dimethylxanthenone-4-acetic acid for use in photoaffinity labeling. J Med Chem 2007, 50(16): 3757-64.
6. Hinnen, P., Eskeens, F.A.L.M. Vascular disrupting agents in clinical development. Br J Cancer 2007, 96(8): 1159-65.
7. Kerr, D.J., Kaye, S.B. Flavone acetic acid - Preclinical and clinical activity. Eur J Cancer 1989, 25(9): 1271-2.
8. Tozer, G.M., Kanthou, C., Baguley, B.C. Disrupting tumour blood vessels. Nat Rev Cancer 2005, 5(6): 423-35.
9. Ching, L.-M., Cao, Z., Kieda, C., Zwain, S., Jameson, M.B., Baguley, B.C. Induction of endothelial cell apoptosis by the anti-vascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 2002, 86(12): 1937-42.
10. Galbraith, S.M., Rustin, G.J.S., Lodge, M.A. et al. Effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002, 20(18): 3826-40.
11. McKeage, M., von Pawel, J. Phase II study of DMXAA (ASA404) 1800 mg/ m2 combined with carboplatin and paclitaxel in non-small cell lung cancer. J Thorac Oncol [12th World Conf Lung Cancer (Sept 2-6, Seoul) 2007] 2007, 2(8, Suppl. 4): Abst P3-116.
12. Pili, R., Rosenthal, M. Randomised phase II study of docetaxel with or without DMXAA (AS1404) in hormone-refractory metastatic prostate cancer (HRMPC). J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 5115.
13. Zwi, L.J., Baguley, B.C., Gavin, J.B., Wilson, W.R. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res 1994, 6(2): 79-85.
14. Ching, L.-M., Zwain, S., Baguley, B.C. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 2004, 90(4): 906-10.
15. Breidahl, T., Neilson, F.U., Stodkilde-Jorgenson, H., Maxwell, R.J., Horsman, M.R. The effects of the vascular disrupting agents combretastatin A-4 disodium, phosphate, 5,6-dimethlyxanthenone-4-acetic acid and ZD6126 in a murine tumour: A comparative assessment using MRI and MRS. Acta Oncol 2006, 45(3): 306-16.
16. Seshadri, M., Mazurchuk, R., Spernyak, J.A., Bhattacharya, A., Rustum, Y.M., Bellnier, D.A. Activity of the vascular-disrupting agent 5,6-dimenthylxanthenone-4-acetic acid against human head and neck carcinoma xenografts. Neoplasia 2006, 8(7): 534-42.
17. Seshadri, M., Spernyak, J.A., Maier, P.G., Cheney, R.T., Mazurchuk, R., Bellnier, D.A. Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: Correlation with endothelial apoptosis, cytokine induction, and treatment. Neoplasia 2007, 9(2): 128-35.
18. McPhail, L.D., Chung, Y.L., Madhu, B., Clark, S., Griffiths, J.R., Kelland, L.R., Robinson, S.P. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. Clin Cancer Res 2005, 11(10): 3705-13.
19. McPhail, L.D., McIntyre, D.J.O., Ludwig, C., Kestell, P., Griffiths, J.R., Kelland, L.R., Robinson, S.P. Rat tumor response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia 2006, 8(3): 199-206.
20. McPhail, L.D., Griffiths, J.R., Kelland, L.R., Robinson, S.P. Assessment of tumor response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2007, 69(4): 1238-45.
21. Liu, J.J., Ching, L.-M., Goldthorpe, M., Sutherland, R., Baguley, B.C., Kirker, K.A., McKeage, M.J. Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours. Cancer Chemother Pharmacol 2007, 59(5): 661-9.
22. Zwi, L.J., Baguley, B.C., Gavin, J.B., Wilson, W. R. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst 1989, 81(13): 1005-13.
23. Manda, T., Hishigawa, F., Mori, J., Shimomura, K. Important role of serotonin in the antitumour effects of tumor necrosis factor-alpha in mice. Cancer Res 1988, 48(15): 4250-5.
24. Baguley, B.C., Zhuang, L., Kestell, P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicines: Relation to vascular effects. Oncol Res 1997, 9(2): 55-60.
25. Kestell, P., Zhao, L.L., Jameson, M.B., Stratford, M.R.L., Folkes, L.K., Baguley, B.C. Measurement of plasma 5-hydroxy-indoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clin Chim Acta 2001, 314(1-2): 159-66.
26. Thomsen, L.L., Ching, L.M., Zhuang, L., Gavin, J.B., Baguley, B.C. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogs in mice. Cancer Res 1991, 51(1): 77-81.
27. Fukumura, D., Jain, R.K. Role of nitric oxide in angiogenesis and microcirculation in tumors. Cancer Metastasis Rev 1998, 17(1): 77-89.
28. Thomsen, L.L., Ching, L.-M., Baguley, B.C. Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid. Cancer Res 1990, 50(21): 6966-70.
29. Joseph, W.R., Cao, Z., Mountjoy, K.G., Marshall, E.S., Baguley, B.C., Ching, L.-M. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: A novel approach to cancer therapy. Cancer Res 1999, 59(3): 633-8.
30. Ching, L.M., Goldsmith, D., Joseph, W.R., Korner, H., Sedgwick, J.D., Baguley, B.C. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knock-out mice. Cancer Res 1999, 59(14): 3304-7.
31. Zhao, L., Ching, L.-M., Kestell, P., Baguley, B.C. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor knock-out mice. Br J Cancer 2002, 87(4): 465-70.
32. Perera, P.Y., Barber, S.A., Ching, L.-M., Vogel, S.N. Activation of LPS-inducible genes by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid in primary murine macrophages - Dissection of signaling pathways leading to gene induction and tyrosine phosphorylation. J Immunol 1994, 153(10): 4684-93.
33. Cao, Z., Baguley, B.C., Ching, L.-M. IP-10 induction and inhibition of angiogrenesis by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Res 2001, 61(4): 1517-21.
34. Jassar, A.S., Suzuki, E., Kapoor, V. et al. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6 dimethylxanthenone-4-acetic acid (DMXAA) induces an effective CD8+ T-cell-mediated anti-tumor immune response in immunogenic and non-immunogenic murine models of lung cancer and mesothelioma. Cancer Res 2005, 65(24): 11752-61.
35. Wang, L.-C.S., Woon, S.-T., Baguley, B.C., Ching, L.-M. Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-κB inhibitors. Oncol Res 2006, 16(1): 1-14.
36. Wallace, A., LaRosa, D.F., Kapoor, V. et al. The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA), directly activates dendritic cells through a MyD88-independent mechanism and generates anti-tumor cytotoxic T-lymphocytes. Cancer Res 2007, 67(14): 7011-9.
37. Roberts, Z.J., Goutagny, N., Perera, P.-Y. et al. The chemotherapeutic agent 5,6-dimethylxanthenone-4-acetic acid, potently and specifically activates the TBK1-IRF-3 signalling axis. J Exp Med 2007, 204(7): 1559-69.
38. Woon, S.-T., Reddy, C.B., Drummond, C.J., Schooltink, M.A., Baguley, B.C., Kieda, C., Ching, L.-M. A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kappaB in murine and human cell lines. Oncol Res 2005, 15(7-8): 351-64.
39. Woon, S.-T., Zwain, S., Schooltink, M.A., Newth, A.L., Baguley, B.C., Ching, L.-M. NF-kappaB activation in vivo in both host and tumour cells by the antivascular agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Eur J Cancer 2003, 39(8): 1176-83.
40. Woon, S.-T., Baguley, B.C., Palmer, B.D., Fraser, J., Ching, L.-M. Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumour cell lines. Oncol Res 2002, 13(2): 95-101.
41. Ching, L.M., Young, H.A., Eberly, K., Yu, C.-R. Induction of STA T and NF kappa B activation by the antitumour agents 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid in a murine macrophage cell line. Biochem Pharmacol 1999, 58(7): 1173-81.
42. Kanwar, J.R., Kanwar, R., Pandey, S., Ching, L.-M., Krissansen, G.W. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1(CD80)-mediated immunotherapy overcomes immume resistance and leads to the eradication of large tumors and multiple foci. Cancer Res 2001, 61(5): 1948-56.
43. Horsman, M.R., Murata, R. Combination of vascular targeting agents with thermal or radiation therapy. Int J Rad Oncol Biol Phys 2002, 54(5): 1518-23.
44. Seshadri, M., Spernyak, J.A., Mazurchak, R., Camacho, S.H., Oseroff, A.R., Cheney, R.T., Bellnier, D.A. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: Implications for combination therapy. Clin Cancer Res 2005, 11(11): 4241-50.
45. Murata, R., Sieman, D.W., Overgaard, J., Horsman, M.R. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res 2001, 156(5): 503-9.
46. Pruijn, F.B., van Daalen, M., Holford, N.H.G., Wilson, W.R. Mechanisms of enhancement of the antitumour activity of melphlan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1997, 39(6): 541-6.
47. Lash, C.J., Li, A.E., Rutland, M., Baguley, B.C., Zwi, L.J., Wilson, W.R. Enhancement of the anti-tumour effects of the anti-vascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 1998, 78(4): 439-45.
48. Siim, B.G., Lee, A.E., Shalal-Zwain, S. et al. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003, 51(1): 43-52.
49. Siemann, D.W., Mercer, E., Lepler, S., Rogiani, A.M. Vascular targeting agents enhance chemotherapeutic agent activaties in solid tumor therapy. Int J Cancer 2002, 99(1): 1-6.
50. Kestell, P., Zhao, L., Baguley, B.C., Palmer, B.D., Muller, G., Paxton, J.W., Ching, L.M. Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-actic acid (DMXAA) by thalidomide. Cancer Chemother Pharmacol 2000, 46(2): 135-41.
51. Ching, L.-M., Browne, W.L., Tchernegovski, R., Gregory, T., Baguley, B.C., Palmer, B.D. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the antitumour agent 5,6-dimethylxanthenone-4-acetic acid: Concomitant reduction of serum tumour necrosis factor-alpha and enhancement of antitumour activity. Br J Cancer 1998, 78(3): 336-43.
52. Ching, L.-M., Xu, Z.-F., Gummer, B.H., Palmer, B.D., Joseph, W.R., Baguley, B.C. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1995, 72(2): 339-43.
53. Chung, F., Lui, J., Ching, L.-M., Baguley, B.C. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide. Cancer Chemother Pharmacol 2008, 61(3): 497-502.
54. Cao, Z., Joseph, W.R., Browne, W.L., Mountjoy, K.G., Palmer, B.D., Baguley, B.C., Ching, L.M. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1999, 80(5-6): 716-23.
55. Chung, F., Wang, L.-C. S., Kestell, P., Baguley, B.C., Ching, L.-M. Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: The role of tumour necrosis factor. Cancer Chemother Pharmacol 2004, 53(5): 377-83.
56. Zhao, L., Kestell, P., Ching, L.-M., Baguley, B.C. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice. Cancer Chemother Pharmacol 2002, 49(1): 20-6.
57. Zhao, L., Ching, L.-M., Kestell, P., Baguley, B.C. Improvement of the antitumour activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling. Clin Cancer Res 2003, 9(17): 6545-50.
58. Kestell, P., Paxton, J.W., Rewcastle, G.W., Dunlop, I., Baguley, B.C. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit. Cancer Chemother Pharmacol 1999, 43(4): 323-30.
59. Zhou, S.F., Kestell, P., Tingle, M.D., Paxton, J.W. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2002, 49(2): 126-32.
60. Zhou, S.F., Paxton, J.W., Kestell, P., Tingle, M.D. Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species. J Pharm Pharmacol 2001, 53(4): 463-71.
61. Zhou, S.F., Paxton, J.W., Tingle, M.D. et al. Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans. Xenobiotica 2001, 31(5): 277-93.
62. Zhou, S.F., Kestell, P., Baguley, B.C., Paxton, J.W. Preclinical factors influencing the relative contributions of phase I and phase II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochem Pharmacol 2003, 65(1): 109-20.
63. Zhou, S., Paxton, J.W., Tingle, M.D., Kestell, P. Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metab Dispos 2000, 28(12): 1449-56.
64. Jameson, M.B., Baguley, B.C., Kestell, P. et al. Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in a phase 1 clinical trial. Cancer Chemother Pharmacol 2007, 59(5): 681-7.
65. Rustin, G.J.S., Bradley, C., Galbraith, S. et al. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 2003, 88(8): 1160-7.
66. McKeage, M., Fong, P., Jeffery, M. et al. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: A Phase 1 safety study of a vascular disrupting agent. Clin Cancer Res 2006, 12(6): 1776-84.
67. Von Pawel, J., Reck, M., McKeague, M. Update on survival in a phase Ib/II study of DMXAA (AS1404) combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). Eur J Cancer Suppl [18th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Nov 7-10, Prague) 2006] 2006, 4(12): Abst 40.
68. Gabra, H., Jameson, M. Update on randomised phase II study of DMXAA (ASA404) combined with carboplatin and paclitaxel in recurrent ovarian cancer. Eur J Cancer Suppl [14th Eur Cancer Conf (ECCO) (Sept 23-27, Barcelona) 2007] 2007, 5(4): Abst 5028.
69. ASA404 or placebo in combination with paclitaxel and carboplatin as first-line treatment for stage IIIb/IV non-small cell lung cancer (NCT00662597). ClinicalTrials.gov Web site, May 27, 2008.
70. An open-label, phase I trial of intravenous ASA404 administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung caner (NSCLC) (NCT00674102). ClinicalTrials.gov Web site, May 27, 2008.
71. Study of AS1404 with docetaxel in patients with hormone refractory metastatic prostate cancer (NCT00111618). ClinicalTrials.gov Web site, May 27, 2008.